New Programs Track Off-Label Use of Targeted Cancer Drugs

Two programs are underway to track off-label use of targeted cancer drugs and patient outcomes, as well as facilitate patient access to these agents. According to Nature News, more than 60% of US prescriptions for cancer drugs are for off-label use—often because patients have a tumor with a feature or

Read more

Stem Cells Account for Different Fates of Adenomatous and Hyperplastic Polyps

Adenomatous polyps expand the pool of colon stem cells to become malignant, whereas hyperplastic polyps (HPPs) do not, and therefore remain benign, according to a study published in the September issue of Gastroenterology. Many colorectal cancers arise from adenomatous polyps, which contain mutations that inactivate the tumor suppressor APC. These

Read more